Clinicopathologic Features and Outcomes of Early-Onset Pancreatic Adenocarcinoma in the United States.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
25
02
2019
pubmed:
3
1
2020
medline:
3
2
2021
entrez:
3
1
2020
Statut:
ppublish
Résumé
Limited research has been performed regarding pancreatic ductal adenocarcinoma (PDAC) diagnosed in early-onset patients. This study defined early-onset disease as cancer diagnosed before the age of 50 years and aimed to characterize the clinicopathologic factors associated with early- versus late-onset patients. The National Cancer Database was queried to identify early- and late-onset PDAC patients with cancer diagnosed from 2004 to 2013. Patient demographics, tumor characteristics, treatment regimens, and overall survival (OS) were compared between the groups. The study enrolled 207,062 patients, including 12,137 early-onset patients (5.9%) and 194,925 late-onset patients (94.1%). The early-onset patients (stage 3 or 4 cancer) were more likely to present with a later stage of disease (62.1% vs. 55.2%; p < 0.001) and to be male (57.1% vs. 50.0%; p < 0.001) than those with late-onset PDAC. The early-onset patients also presented with a lower Charlson/Deyo comorbidity score (80.9% vs. 66.6% had a score of 0; p < 0.001) and received higher rates of treatment (22.8% vs. 40.1% received no treatment, p < 0.001) than the late-onset patients. Furthermore, early-onset PDAC was associated with improved OS among all the PDAC patients (9.2 vs. 6.0 months; p < 0.001) and among the surgically resected patients (27.3 vs. 24.3 months; p < 0.001). Early-onset PDAC also was found to be independently associated with improved OS after adjustment for other significant clinicopathologic factors. Despite features suggestive of aggressive tumor biology at presentation, early-onset PDAC was independently associated with better OS than late-onset PDAC among all patients and among curatively resected stage-matched patients.
Sections du résumé
BACKGROUND
BACKGROUND
Limited research has been performed regarding pancreatic ductal adenocarcinoma (PDAC) diagnosed in early-onset patients. This study defined early-onset disease as cancer diagnosed before the age of 50 years and aimed to characterize the clinicopathologic factors associated with early- versus late-onset patients.
METHODS
METHODS
The National Cancer Database was queried to identify early- and late-onset PDAC patients with cancer diagnosed from 2004 to 2013. Patient demographics, tumor characteristics, treatment regimens, and overall survival (OS) were compared between the groups.
RESULTS
RESULTS
The study enrolled 207,062 patients, including 12,137 early-onset patients (5.9%) and 194,925 late-onset patients (94.1%). The early-onset patients (stage 3 or 4 cancer) were more likely to present with a later stage of disease (62.1% vs. 55.2%; p < 0.001) and to be male (57.1% vs. 50.0%; p < 0.001) than those with late-onset PDAC. The early-onset patients also presented with a lower Charlson/Deyo comorbidity score (80.9% vs. 66.6% had a score of 0; p < 0.001) and received higher rates of treatment (22.8% vs. 40.1% received no treatment, p < 0.001) than the late-onset patients. Furthermore, early-onset PDAC was associated with improved OS among all the PDAC patients (9.2 vs. 6.0 months; p < 0.001) and among the surgically resected patients (27.3 vs. 24.3 months; p < 0.001). Early-onset PDAC also was found to be independently associated with improved OS after adjustment for other significant clinicopathologic factors.
CONCLUSIONS
CONCLUSIONS
Despite features suggestive of aggressive tumor biology at presentation, early-onset PDAC was independently associated with better OS than late-onset PDAC among all patients and among curatively resected stage-matched patients.
Identifiants
pubmed: 31894482
doi: 10.1245/s10434-019-08096-y
pii: 10.1245/s10434-019-08096-y
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1997-2006Subventions
Organisme : Veterans Affairs North Texas Health Care System (PMP)
ID : New Investigator Award Grant
Références
American Cancer Society. Cancer Facts & Figures 2018. American Cancer Society, Atlanta, 2018.
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.
doi: 10.1158/0008-5472.CAN-14-0155
Muniraj T, Jamidar PA, Aslanian HR. Pancreatic cancer: a comprehensive review and update. Dis Mon. 2013;59:368–402.
doi: 10.1016/j.disamonth.2013.08.001
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
doi: 10.3322/caac.21551
American Cancer Society. Cancer Facts & Figures 2013. American Cancer Society, Atlanta, 2013.
Raimondi S, Maisonneuve P, Lohr JM, Lowenfels AB. Early-onset pancreatic cancer: evidence of a major role for smoking and genetic factors. Cancer Epidemiol Biomark Prev. 2007;16:1894–7.
doi: 10.1158/1055-9965.EPI-07-0341
McWilliams RR, Maisonneuve P, Bamlet WR, et al. Risk factors for early-onset and very-early-onset pancreatic adenocarcinoma: a pancreatic cancer case–control consortium (PanC4) analysis. Pancreas. 2016;45:311–6.
doi: 10.1097/MPA.0000000000000392
Ries LAG YJ, Keel GE, Eisner MP, Lin YD, Horner M-J (eds). SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988–2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. no. 07-6215, Bethesda, MD, 2007. Retrieved 23 Dec 2019 at https://seer.cancer.gov/archive/publications/survival/index.html .
Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol. 2007;14:1320–6.
doi: 10.1245/s10434-006-9249-8
Beeghly-Fadiel A, Luu HN, Du L, et al. Early-onset pancreatic malignancies: clinical characteristics and survival associations. Int J Cancer. 2016;139:2169–77.
doi: 10.1002/ijc.30273
He J, Edil BH, Cameron JL, et al. Young patients undergoing resection of pancreatic cancer fare better than their older counterparts. J Gastrointest Surg. 2013;17:339–44.
doi: 10.1007/s11605-012-2066-4
IBM Corp. Released 2017. IBM SPSS Statistics for Windows, version 25.0. IBM Corp, Armonk, NY.
Piciucchi M, Capurso G, Valente R, et al. Early-onset pancreatic cancer: risk factors, presentation, and outcome. Pancreatology. 2015;15:151–5.
doi: 10.1016/j.pan.2015.01.013
Duffy A, Capanu M, Allen P, et al. Pancreatic adenocarcinoma in a young patient population: 12-year experience at Memorial Sloan Kettering Cancer Center. J Surg Oncol. 2009;100:8–12.
doi: 10.1002/jso.21292
Lin JC, Chan DC, Chen PJ, et al. Clinical characteristics of early-onset pancreatic adenocarcinoma: a medical center experience and review of the literature. Pancreas. 2011;40:638–9.
doi: 10.1097/MPA.0b013e318214fe56
Tingstedt B, Weitkamper C, Andersson R. Early-onset pancreatic cancer: a controlled trial. Ann Gastroenterol. 2011;24:206–12.
pubmed: 24713777
pmcid: 3959307
Abraham A, Al-Refaie WB, Parsons HM, Dudeja V, Vickers SM, Habermann EB. Disparities in pancreas cancer care. Ann Surg Oncol. 2013;20:2078–87.
doi: 10.1245/s10434-012-2843-z
Walker GV, Grant SR, Guadagnolo BA, et al. Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status. J Clin Oncol. 2014;32:3118–25.
doi: 10.1200/JCO.2014.55.6258
Ahnen DJ, Wade SW, Jones WF, et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89:216–24.
doi: 10.1016/j.mayocp.2013.09.006
Fu J, Yang J, Tan Y, et al. Young patients (≤ 35 years old) with colorectal cancer have worse outcomes due to more advanced disease: a 30-year retrospective review. Med Baltimore. 2014;93:e135.
doi: 10.1097/MD.0000000000000135
Dobbins TA, Badgery-Parker T, Currow DC, Young JM. Assessing measures of comorbidity and functional status for risk adjustment to compare hospital performance for colorectal cancer surgery: a retrospective data-linkage study. BMC Med Inform Decis Mak. 2015;15:55.
doi: 10.1186/s12911-015-0175-1
Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017;3:1722–8.
doi: 10.1001/jamaoncol.2016.6905
Luttges J, Stigge C, Pacena M, Kloppel G. Rare ductal adenocarcinoma of the pancreas in patients younger than age 40 years. Cancer. 2004;100:173–82.
doi: 10.1002/cncr.11860
Ntala C, Debernardi S, Feakins RM, Crnogorac-Jurcevic T. Demographic, clinical, and pathological features of early onset pancreatic cancer patients. BMC Gastroenterol. 2018;18:139.
doi: 10.1186/s12876-018-0866-z